One To Watch

Upstream Bio

A clinical-stage biotechnology company developing long-acting biologics for severe inflammatory respiratory diseases. Its pipeline is anchored by verekitug, a monoclonal antibody that antagonizes the thymic stromal lymphopoietin (TSLP) receptor.

Company Overview

Upstream Bio focuses on upstream inflammatory biology in respiratory disease, aiming to deliver durable control with less frequent dosing. The company’s current strategy is built around advancing a single lead asset across multiple indications where TSLP-driven inflammation is implicated.

Headquarters and Global Presence

Upstream Bio is based in Waltham, Massachusetts. Its clinical program is run through global, placebo-controlled randomized studies in respiratory indications.

Founding and History

Upstream Bio became a public company in October 2024, listing on Nasdaq under ticker UPB following an upsized IPO.

Therapy Areas and Focus

Upstream’s disclosed focus is severe respiratory disease, including:

Severe asthma
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Chronic obstructive pulmonary disease (COPD)

Technology Platforms and Modalities

Upstream’s lead modality is a fully human IgG1 monoclonal antibody designed to inhibit signaling through the TSLP receptor. The development thesis is that blocking this upstream pathway can reduce downstream inflammatory cascades relevant to multiple respiratory phenotypes.

Programs and Clinical Pipeline

Verekitug (TSLP receptor antagonist; monoclonal antibody)

Severe asthma: Phase II (VALIANT) top-line results reported February 11, 2026; program positioned for Phase III dose-selection and regulatory discussions
CRSwNP: Phase II (VIBRANT) completed (company has described this as a global, placebo-controlled randomized trial)
COPD: Phase II ongoing (global, placebo-controlled randomized)
Long-term follow-up: an extension study (VALOUR) has been used to follow patients completing the asthma study

Key Personnel

Rand Sutherland, MD, Chief Executive Officer
Aaron Deykin, MD, Chief Medical Officer and Head of R&D
Mike Gray, MBA, Chief Financial Officer and Chief Operating Officer
Adam Houghton, PhD, Chief Business Officer
Allison Ambrose, General Counsel
Stacy Price, MS, PMP, Chief Technology Officer

Strategic Positioning

Upstream is positioning verekitug as a long-acting TSLP-pathway therapy, with development choices shaped by dosing interval feasibility and competitiveness in a market that already includes a commercial TSLP-pathway biologic (tezepelumab).

FAQ Section

Upstream’s core approach is antagonism of the TSLP receptor using a long-acting monoclonal antibody. The intent is to suppress upstream inflammatory signaling that contributes to severe respiratory disease across multiple phenotypes.

The company is focused on severe respiratory indications where TSLP-driven inflammation is relevant: severe asthma, CRSwNP and COPD. Current activity is centered on these three disease areas rather than a broad multi-asset pipeline.

Upstream’s disclosed pipeline is led by a single clinical-stage program, verekitug, developed in parallel across:

Severe asthma (Phase II)
CRSwNP (Phase II)
COPD (Phase II)

Most recent items, in reverse chronological order:

February 11, 2026: reported top-line Phase II VALIANT results for verekitug in severe asthma; the quarterly (every 12 weeks) regimen was the more compelling efficacy readout versus the longer-interval arm, based on company and market reporting of the data.
October 2024: completed an upsized IPO and began trading on Nasdaq as UPB.

For severe asthma, Upstream reported Phase II VALIANT top-line results on February 11, 2026, including reductions in annualized exacerbations and improvements in lung function and inflammatory biomarkers, with the quarterly dosing regimen emerging as the more competitive profile. Detailed subgroup and durability interpretation will depend on full dataset disclosure and subsequent Phase III design choices.

Key milestones are execution- and design-dependent:

Final dose and dosing-interval selection for Phase III in severe asthma
Phase III initiation planning in severe asthma and CRSwNP following regulatory discussions
Progression and readout timing for the ongoing Phase II COPD study
Longer-term safety and durability readouts from extension follow-up

The differentiation case is primarily product-profile based: verekitug is being developed to support less frequent dosing. Whether it can be meaningfully differentiated will depend on (a) the reproducibility of efficacy at the intended dosing interval, (b) tolerability/safety at that interval, and (c) the strength of Phase III endpoints versus established standards in severe asthma and CRSwNP.

Want to Update your Company's Profile?